转自：扬子晚报 记者了解到，自2025年11月10日起，HPV疫苗正式纳入国家免疫规划，江苏省同步落地实施相关政策， 为符合条件的适龄女孩提供免费接种服务。 为什么要将HPV疫苗纳入国家免疫规划？为何国家免疫规划HPV疫苗的目标人群为13周岁女孩？记者请 教了江苏省疾病预防控制中心免规所专家。 图源 视觉中国 1.为什么要将HPV疫苗纳入国家免疫规划？ 宫颈癌是女性生殖系统最常见的恶性肿瘤之一。及时接种HPV疫苗能够有效地降低宫颈癌的发生风险。 经国务院同意，决定自2025年11月10日起，在现行国家免疫规划疫苗基础上，将HPV疫苗纳入国家免疫 规划，组织各地为2011年11月10日以后出生的满13周岁女孩免费接种2剂次双价HPV疫苗（间隔6个 月）。 2.为何国家免疫规划HPV疫苗的目标人群为13周岁女孩？ HPV主要通过性行为感染，在发生性行为年龄之前进行HPV疫苗接种，可以获得更好的保护效果，最大 限度发挥疫苗预防HPV感染的作用。 相关研究表明，9—14岁女孩接种HPV疫苗产生的抗体水平，是15岁以上人群的2倍以上。接种HPV疫苗 可以有效预防70%以上的宫颈癌发生，同时也可以降低因感染HPV导致的其 ...

李筱翠说，有研究表明，9-14周岁的女孩接种HPV疫苗产生的抗体水平，是15周岁以上人群的2倍以 上，保护效果可持续10年以上。国家每年为13周岁的女孩免费接种HPV疫苗，主要也是考虑这个年龄段 的女孩，能够产生更高的抗体水平和更持久的保护效果，最大限度地发挥疫苗的预防作用。 目前我国上市使用的HPV疫苗有多种不同价次，纳入国家免疫规划的是双价的HPV疫苗，需要接种2剂 次，间隔6个月。李筱翠介绍，从保护效果来看，双价HPV疫苗可有效预防70%以上的宫颈癌，还可以 降低因感染HPV导致的其他疾病的发生。 中国青年报客户端北京2月12日电（中青报·中青网记者 刘昶荣）"近年来，我国宫颈癌呈现发病率上升 和年轻化的趋势，严重威胁女性身心健康。"在国家卫生健康委今天下午召开的新闻发布会上，国家疾 控局卫生免疫司司长李筱翠表示，接种HPV疫苗，能够有效预防高危型HPV感染，减少宫颈癌等疾病发 生，是一种最经济、最有效的预防手段。 今天发布会的主题是，介绍为民服务实事有关部署情况。为巩固拓展2025年卫生健康系统为民服务实事 成效，国家卫生健康委、国家中医药局、国家疾控局决定2026年继续在全国卫生健康系统组织实施一批 ...

Core Viewpoint - Nepal's Ministry of Health and Population is launching a nationwide HPV vaccination campaign from February 8 to 27 to prevent cervical cancer among schoolgirls and out-of-school girls aged 10 to 14 [1] Group 1: Vaccination Campaign Details - The vaccination campaign targets all sixth-grade schoolgirls, 10-year-old out-of-school girls, and girls in grades seven to ten who missed vaccination last year, as well as out-of-school girls aged 11 to 14 [1] - Vaccination points will be set up at schools, nearby locations, or designated healthcare facilities, with arrangements varying by region [1] Group 2: Public Health Initiative - The Ministry of Health urges parents, guardians, and relevant parties to ensure eligible girls receive the vaccine during this period to collectively reduce the risk of cervical cancer [1]

Core Viewpoint - The province has successfully exceeded its goal of vaccinating 100,000 eligible girls with the HPV vaccine, aiming to prevent cervical cancer and promote public health [1][2]. Group 1: Project Implementation - The provincial government established a collaborative mechanism involving multiple departments to ensure the effective implementation of the HPV vaccination project [3]. - A temporary management method for vaccination subsidy funds was introduced to standardize the subsidy process and ensure proper fund allocation [3]. - After the first dose was administered, the government organized data verification to ensure compliance with the vaccination plan and maintain accurate records [3]. Group 2: Public Awareness and Education - A comprehensive promotional network was created to address parents' and girls' concerns about the HPV vaccine, utilizing both online and offline channels [4]. - The government produced educational materials and engaged experts to disseminate knowledge about cervical cancer prevention and the importance of vaccination [4]. - Local governments leveraged various media platforms to raise awareness about the HPV vaccine and its benefits, ensuring that the community is well-informed [4]. Group 3: Service Optimization - Vaccination sites were organized efficiently, with healthcare professionals ensuring safety protocols were followed during the vaccination process [5][6]. - The health department provided educational resources to enhance understanding of the vaccination process and offered extended service hours for convenience [6]. - Regular monitoring and coordination were conducted to address challenges in vaccine distribution and ensure the smooth execution of the vaccination program [6].

Core Viewpoint - Gansu Province has become the first in Northwest China to include HPV vaccination for eligible girls in its provincial public welfare initiatives, aiming to provide vaccination services to 100,000 girls by the end of 2025, reflecting a strong commitment to women's and children's health [1][11]. Group 1: Implementation Strategy - A three-tiered working system has been established, involving provincial coordination, departmental collaboration, and local implementation, with clear policies and funding support to ensure effective project execution [2][4]. - Specific implementation plans and subsidy management guidelines have been developed, detailing the vaccination process, target demographics, and departmental responsibilities [2]. Group 2: Public Awareness and Engagement - A multi-faceted promotional strategy has been created to address common concerns about vaccine safety and necessity, utilizing both online and offline channels to enhance public awareness and acceptance [5][7]. - Innovative outreach efforts have been made, including personalized communication strategies for families and targeted campaigns in areas with high numbers of left-behind children [7][9]. Group 3: Service Quality and Safety - The vaccination process has been optimized to ensure safety and efficiency, with comprehensive data collection and dynamic information management to track eligible girls [8][11]. - A focus on human-centered service has been implemented, providing various support services at vaccination sites and flexible scheduling options to accommodate different needs [9][11]. - Rigorous quality control measures have been established, including extensive training for vaccination personnel and strict adherence to safety protocols, resulting in zero major adverse reactions reported so far [11]. Group 4: Future Directions - Gansu Province plans to further enhance its women's and children's health service system by integrating various health initiatives, aiming to improve overall health outcomes for women and children in the region [11].

Core Viewpoint - Zhejiang Province is implementing HPV vaccination initiatives to enhance public health and prevent related diseases, particularly cervical cancer, by providing subsidized access to the HPV vaccine for eligible populations [1][2]. Group 1: HPV Vaccination Initiatives - The HPV vaccination program in Zhejiang will offer subsidized access to the imported nine-valent HPV vaccine for females aged 9-26 and 35-45, as well as males aged 16-26, with the last dose being free of charge [1]. - The vaccination initiative has received positive social feedback, leading to an extension of the vaccination period to accommodate demand, with the first dose deadline set for September 30, 2026, in most cities [2]. - The program aims to provide protection for women beyond the national immunization age and includes male vaccination, thereby broadening the health care support system [2]. Group 2: HPV Infection and Prevention - HPV is a common infection with over 200 types, with high-risk types being responsible for approximately 98% of cervical cancer cases in Chinese women [3][4]. - The incidence of cervical cancer in China is rising, with nearly 150,000 new cases and 60,000 deaths reported in 2022, highlighting the importance of preventive measures such as vaccination [3]. - The World Health Organization recommends that girls aged 9-14, who have not yet engaged in sexual activity, are the primary target group for HPV vaccination to achieve optimal protection [3]. Group 3: Gender Considerations in HPV Vaccination - HPV infection rates show a "bimodal" distribution among women, with peaks at ages 17-24 and 40-44, indicating the need for vaccination across different age groups [4]. - Men are also significantly affected by HPV, with a lifetime infection rate of approximately 90%, and the vaccination of both genders is essential to reduce overall infection rates and associated health risks [5][6]. - The collaborative vaccination strategy for both genders is expected to lower HPV infection rates and reduce healthcare costs related to screening and treatment [5]. Group 4: Public Health Strategy and Accessibility - The clinical guidelines recommend prioritizing HPV vaccination for females aged 9-26, with a focus on girls aged 9-14, while also including males and older females in the vaccination strategy [6]. - Zhejiang's multi-faceted approach to promoting HPV vaccination reflects a commitment to public health and aims to establish a herd immunity barrier by making vaccinations more accessible and affordable [6].

Core Viewpoint - Cervical cancer is a common malignant tumor in the female reproductive system, and the HPV vaccine is the most effective means of prevention [1] Group 1: HPV Vaccine Efficacy - The HPV vaccine stimulates the immune system to produce protective antibodies that can quickly eliminate the virus upon invasion [1] - Widespread vaccination can reduce the incidence of cervical cancer by over 70% [1] - The vaccine also significantly decreases the risk of diseases caused by HPV types 16 and 18 [1]

Core Viewpoint - Jiangsu Province is implementing HPV vaccination initiatives to enhance public health and prevent cervical cancer, aligning with national health strategies and local action plans [1][2]. Group 1: HPV Vaccination Initiatives - Starting in 2023, Jiangsu Province has included "free HPV vaccination for eligible girls" in its government welfare projects for three consecutive years, targeting first-year middle school girls [2]. - Various cities in Jiangsu are offering financial incentives for HPV vaccinations, significantly reducing economic burdens and increasing vaccination willingness among the population [2]. - The vaccination program has expanded to include women aged 9-26 and men aged 16-26, with specific financial incentives for receiving the imported nine-valent HPV vaccine [2][3]. Group 2: Health Statistics and Trends - HPV infection is common, with high-risk types causing approximately 98% of cervical cancer cases in Chinese women, highlighting the importance of early vaccination [4]. - The incidence of cervical cancer in China is rising, with nearly 150,000 new cases and 60,000 deaths reported in 2022, indicating a need for preventive measures [4]. - The age distribution of HPV infections shows peaks at 17-24 years and 40-44 years, emphasizing the necessity of vaccination across different age groups [5]. Group 3: Broader Health Implications - HPV is not exclusive to women; men also face significant health risks, with a lifetime infection rate of about 90%, which can lead to various cancers [5][6]. - Joint vaccination strategies for both genders can significantly reduce HPV infection rates and associated healthcare costs, facilitating the goal of cervical cancer elimination [6]. Group 4: Accessibility and Public Awareness - The vaccination program aims to create a robust immunity barrier by including diverse age groups and genders, thus promoting community health [7]. - Local vaccination policies have varying deadlines, and eligible individuals are encouraged to consult local health services to plan their vaccinations effectively [3][7].

Core Viewpoint - The first domestic nine-valent HPV vaccine was launched in Sichuan on December 18, providing an effective means to prevent cervical cancer, which is primarily caused by high-risk HPV infections [1] Group 1: Vaccine Information - HPV is the main cause of cervical cancer, with 99.7% of cases linked to persistent high-risk HPV infections [1] - The nine-valent HPV vaccine covers more high-risk virus subtypes compared to the two-valent and four-valent vaccines, offering broader protection [1] - The price of the domestic nine-valent HPV vaccine is 509 yuan per dose [1] Group 2: Target Population and Dosage - The vaccine is recommended for females aged 9 to 45 years, with a suggested dosage of 2 doses for those aged 9 to 17 and 3 doses for those aged 18 to 45 [1] - Eligible women can consult and make appointments through the "Sichuan Vaccination" WeChat official account [1] Group 3: Appointment and Administration - On the day of vaccination, individuals must bring valid identification, and minors need to be accompanied by a family member [1] - Vaccination appointment availability will gradually open across various locations in the province, and interested individuals are encouraged to stay updated [1]

Core Viewpoint - The launch of the first domestically produced nine-valent HPV vaccine in Shanghai provides a new option for cervical cancer prevention for women aged 9 to 45 [1] Group 1: Vaccine Approval and Significance - The nine-valent HPV vaccine, named "Xinkening 9," developed by Wantai Biological Pharmacy, received approval from the National Medical Products Administration in June 2025, making it the first domestically approved nine-valent HPV vaccine and the second globally [1] - Cervical cancer is one of the most common malignant tumors threatening women's health worldwide and is the only cancer that can be prevented through vaccination [1] Group 2: Vaccine Efficacy and Pricing - Research indicates that the vaccine effectively protects against infections from nine types of HPV that can lead to cervical cancer and related diseases [1] - The vaccine is priced at 499 yuan per dose, with a total cost of 998 yuan for a two-dose regimen for females aged 9-17, and 1497 yuan for a three-dose regimen for females aged 18-45 [1] Group 3: Implementation and Distribution - Shanghai has fully launched the vaccination service for the domestically produced nine-valent HPV vaccine, with the first batch of vaccines being delivered to community health service centers across the city [1]